Scarica l'app Stockscreener
0.9516
4.25%
0.0364
Precedente Chiudi:
$0.9152
Aprire:
$0.8956
Volume 24 ore:
213.31K
Relative Volume:
0.29
Capitalizzazione di mercato:
$115.98M
Reddito:
$3.25M
Utile/perdita netta:
$-116.80M
Rapporto P/E:
-0.312
EPS:
-3.05
Flusso di cassa netto:
$-98.17M
1 W Prestazione:
+8.59%
1M Prestazione:
-17.75%
6M Prestazione:
-57.22%
1 anno Prestazione:
-88.26%
Intervallo 1D:
$0.8956
$0.9988
Intervallo di 1 settimana:
$0.8471
$0.9988
Portata 52W:
$0.7535
$8.58
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Nome
Rapt Therapeutics Inc
Settore
Industria
Telefono
(650) 489-9000
Indirizzo
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Confronta RAPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
0.9526 | 115.98M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.77 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
615.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
652.80 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
260.82 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.46 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Downgrade | Stifel | Buy → Hold |
| 2024-11-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-02-22 | Downgrade | UBS | Buy → Neutral |
| 2024-02-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Iniziato | Evercore ISI | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-09-14 | Iniziato | Berenberg | Buy |
| 2023-08-09 | Iniziato | Stifel | Buy |
| 2023-06-15 | Iniziato | Barclays | Overweight |
| 2023-01-04 | Iniziato | Guggenheim | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | CapitalOne | Overweight |
| 2022-05-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Iniziato | JP Morgan | Overweight |
| 2021-08-12 | Iniziato | SVB Leerink | Outperform |
| 2021-06-21 | Iniziato | Piper Sandler | Overweight |
| 2020-06-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Iniziato | ROTH Capital | Buy |
| 2019-11-25 | Iniziato | BMO Capital Markets | Outperform |
| 2019-11-25 | Iniziato | UBS | Buy |
| 2019-11-25 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Rapt Therapeutics Inc Borsa (RAPT) Ultime notizie
There is no way RAPT Therapeutics Inc (RAPT) can keep these numbers up - Sete News
A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - uspostnews.com
Market Recap: RAPT Therapeutics Inc (RAPT)’s Positive Momentum, Closing at 0.93 - DWinneX
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Acquired by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
RAPT Therapeutics Inc (RAPT) is a good investment, but the stock may be overvalued - uspostnews.com
Stock Surge: RAPT Therapeutics Inc (RAPT) Closes at 0.79, Marking a -1.32 Increase/Decrease - DWinneX
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth? - Yahoo Finance
RAPT stock touches 52-week low at $0.78 amid sharp annual decline - Investing.com Canada
RAPT stock touches 52-week low at $0.78 amid sharp annual decline By Investing.com - Investing.com South Africa
Rapt Therapeutics appoints Jessica Savage as VP, clinical development - TipRanks
RAPT Therapeutics (RAPT) Strengthens Leadership with New VP for Clinical Development | RAPT Stock News - GuruFocus
RAPT Therapeutics Deepens Expertise in Allergic Diseases - GlobeNewswire
Top Allergy Expert Joins RAPT to Accelerate Novel Food Allergy Treatment Pipeline - Stock Titan
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World
40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co. - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World
Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World
RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright maintains $10 target on RAPT Therapeutics stock By Investing.com - Investing.com Canada
RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks
RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan
Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks
RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks
RAPT Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RAPT THERAPEUTICS Earnings Results: $RAPT Reports Quarterly Earnings - Nasdaq
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
RAPT Therapeutics, Inc. SEC 10-K Report - TradingView
Rapt Therapeutics reports Q4 EPS ($1.14), consensus (36c) - TipRanks
Can RAPT's $231M War Chest and New Food Allergy Drug Transform Its Future? - StockTitan
RAPT Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World
Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
SG Americas Securities LLC Purchases 42,636 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Leerink Partnrs Has Positive Outlook of RAPT FY2024 Earnings - Armenian Reporter
FY2024 Earnings Forecast for RAPT Issued By Leerink Partnrs - Defense World
All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy - Yahoo Finance
RAPT Therapeutics Inc (NASDAQ: RAPT) Up 31.9% From 52-Week Low; YTD Falls -26.58% – Here’s What To Do Now - Marketing Sentinel
A stock that deserves closer examination: Solidion Technology Inc (STI) - US Post News
Analytical Lens: Exploring RAPT Therapeutics Inc (RAPT)’s Financial Story Through Ratios - The Dwinnex
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com
SEC Form 424B3 filed by RAPT Therapeutics Inc. - Quantisnow
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - MSN
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stake Boosted by Barclays PLC - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by Jane Street Group LLC - Defense World
Rapt Therapeutics Inc Azioni (RAPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.01%
2.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):